Cancer Family
Malignant Skin Neoplasm
CI-CAN-00000250Explore in graph →
320 active trials14 approved drugs64 evidence items
- NCIt
- C2920
Loading cancer entity…
Cancer Family
CI-CAN-00000250Explore in graph →
Clinical trials
1,248 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (202)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01823679 | Capecitabine in Treating Patients With Advanced or Recurrent Squamous Cell Carcinoma of the Skin | terminated | Phase 2 | 2 | Stanford UniversityOTHER | 1 | Apr 12, 2018 | clinicaltrials |
| NCT01984892 | Treatment of Solid Tumors With Intratumoral Hiltonol® (Poly-ICLC)(Hiltonol) | terminated | Phase 2 | 8 | Nina BhardwajOTHER | 1 | Jan 23, 2018 | clinicaltrials |
| NCT01187446 | Low-dose (12 Gy) TSEBT+Vorinostat Versus Low-dose TSEBT Monotherapy in Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 28 | Stanford UniversityOTHER | 1 | Nov 20, 2017 | clinicaltrials |
| NCT02076243 | Treatment With Nab-paclitaxel in Cutaneous SCC | terminated | Phase 2 | 2 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 25, 2017 | clinicaltrials |
| NCT02111863 | Immunotherapy Using 41BB Selected Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 6 | National Cancer Institute (NCI)NIH | 1 | Sep 19, 2017 | clinicaltrials |
| NCT01271907 | Drosophila-generated CTL | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Aug 1, 2017 | clinicaltrials |
| NCT01076270 | Plerixafor and Filgrastim For Mobilization of Donor Peripheral Blood Stem Cells Before A Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | terminated | N/A | 1 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 28, 2017 | clinicaltrials |
| NCT00985140 | Phase 2 Total Skin Electron Beam Therapy (TSEBT 12 Gy) in Stage IB-IIIA Mycosis Fungoides | terminated | — | 13 | Stanford UniversityOTHER | 1 | Jun 2, 2017 | clinicaltrials |
| NCT01059305 | Phase II Trial of Erlotinib, Prior to Surgery or Radiation in Patients With Squamous Cell Cancers (SCC) of the Skin | terminated | Phase 2 | 10 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 4, 2017 | clinicaltrials |
| NCT01637090 | Everolimus in Treating Cutaneous T-cell Lymphoma(CTCL) | terminated | Phase 2 | 3 | Adam LernerOTHER | 1 | Jan 12, 2017 | clinicaltrials |
| NCT01307618 | Vaccine Therapy With or Without Recombinant Interleukin-12 Followed by Daclizumab in Treating Patients With Metastatic Melanoma | terminated | Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Oct 24, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01468818 | Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Melanoma | terminated | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Jun 27, 2016 | clinicaltrials |
| NCT01556828 | Analysis of Cutaneous and Hematologic Disorders by High-Throughput Nucleic Acid Sequencing | terminated | — | 70 | Stanford UniversityOTHER | 1 | Jun 24, 2016 | clinicaltrials |
| NCT01808950 | Efficacy and Safety Trial of Topical Resiquimod Gel (0.06%) in Patients With Nodular Basal Cell Carcinoma | terminated | Phase 1 / Phase 2 | 4 | Spirig Pharma Ltd.INDUSTRY | 2 | Jun 22, 2016 | clinicaltrials |
| NCT01120275 | Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Stage IV Melanoma | terminated | Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jun 14, 2016 | clinicaltrials |
| NCT01045928 | Lenalidomide And Rituximab as Maintenance Therapy in Treating Patients With B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 5 | Case Comprehensive Cancer CenterOTHER | 1 | Nov 26, 2015 | clinicaltrials |
| NCT01236573 | Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes | terminated | Phase 1 / Phase 2 | 34 | National Institutes of Health Clinical Center (CC)NIH | 1 | Nov 26, 2015 | clinicaltrials |
| NCT00610311 | Anti-gp100 Cells Plus ALVAC gp100 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT00612222 | Anti-MART-1 F5 Cells Plus ALVAC MART-1 Vaccine to Treat Advanced Melanoma | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Oct 28, 2015 | clinicaltrials |
| NCT01495572 | Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells | terminated | Phase 2 | 5 | National Cancer Institute (NCI)NIH | 1 | Oct 15, 2015 | clinicaltrials |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection | terminated | Phase 1 | 72 | National Cancer Institute (NCI)NIH | 1 | Aug 20, 2015 | clinicaltrials |
| NCT00274651 | A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell Lymphomas(PXD101-CLN-6) | terminated | Phase 2 | 53 | Valerio TherapeuticsINDUSTRY | 5 | Jul 28, 2015 | clinicaltrials |
| NCT00129415 | Ultraviolet (UVA and UVB) Light Therapy in the Treatment of Inflammatory Skin Conditions | terminated | Phase 1 / Phase 2 | 28 | University of MichiganOTHER | 1 | May 22, 2015 | clinicaltrials |
| NCT00278018 | Peritumoral Injection of Immature Dendritic Cells to Irradiated Skin Metastases of Solid Tumors | terminated | Phase 1 / Phase 2 | 20 | Hadassah Medical OrganizationOTHER | 1 | Apr 21, 2015 | clinicaltrials |
| NCT00994240 | Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC | terminated | N/A | 85 | University of Wisconsin, MadisonOTHER | 1 | Feb 27, 2015 | clinicaltrials |
| NCT01369888 | Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 3 | National Cancer Institute (NCI)NIH | 1 | Jan 27, 2015 | clinicaltrials |
| NCT01193036 | Symptom Burden in Patients With Cancer- and Treatment-Related Skin Problems | terminated | — | 11 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 8, 2015 | clinicaltrials |
| NCT00002947 | Indium In 111 Pentetreotide in Treating Patients With Refractory Cancer | terminated | Phase 1 | 35 | Yale UniversityOTHER | 1 | Jul 2, 2014 | clinicaltrials |
| NCT00089076 | MDX-010 in Treating Patients With Recurrent or Refractory Lymphoma | terminated | Phase 1 / Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | May 30, 2014 | clinicaltrials |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane Hydrochloride in Treating Young Patients With Relapsed or Refractory Solid Tumors, Lymphoma, or Leukemia | terminated | Phase 1 | 22 | National Cancer Institute (NCI)NIH | 2 | May 1, 2014 | clinicaltrials |
| NCT00863395 | Recalcitrant Pruritus in Cutaneous T-Cell Lymphoma(CTCL) | terminated | Phase 1 / Phase 2 | 6 | University of MinnesotaOTHER | 1 | Mar 31, 2014 | clinicaltrials |
| NCT02080962 | Hypofractionated Radiotherapy for Nonmelanoma Skin Cancer | terminated | Phase 2 | 10 | Barretos Cancer HospitalOTHER | 1 | Mar 7, 2014 | clinicaltrials |
| NCT00096005 | Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT00101205 | Oxaliplatin, Ifosfamide and Etoposide in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma | terminated | Phase 1 | 40 | National Cancer Institute (NCI)NIH | 1 | Feb 24, 2014 | clinicaltrials |
| NCT01010334 | Comparison of Standard of Care or Treatment on Protocol | terminated | N/A | 13 | New Mexico Cancer Research AllianceOTHER | 1 | Aug 14, 2013 | clinicaltrials |
| NCT00103272 | 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer | terminated | Phase 1 | 74 | National Cancer Institute (NCI)NIH | 1 | Jun 4, 2013 | clinicaltrials |
| NCT00354185 | PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma | terminated | Phase 1 | 36 | National Cancer Institute (NCI)NIH | 1 | May 16, 2013 | clinicaltrials |
| NCT00060112 | Oblimersen and Gemcitabine in Treating Patients With Advanced Solid Tumor or Lymphoma | terminated | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Jan 25, 2013 | clinicaltrials |
| NCT00005982 | 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma | terminated | Phase 2 | 35 | National Cancer Institute (NCI)NIH | 1 | Jan 23, 2013 | clinicaltrials |
| NCT00052377 | Interleukin-12 and Interleukin-2 in Treating Patients With Mycosis Fungoides | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jan 16, 2013 | clinicaltrials |
| NCT00509496 | Phase II Study of Metastatic Melanoma With Lymphodepleting Conditioning and Anti-gp100:154-162 TCR Gene Engineered Lymphocytes | terminated | Phase 2 | 21 | National Cancer Institute (NCI)NIH | 1 | Jan 15, 2013 | clinicaltrials |
| NCT00003613 | O6-benzylguanine and Carmustine in Treating Patients With Stage IA-IIA Cutaneous T-cell Lymphoma | terminated | Phase 1 | 20 | National Cancer Institute (NCI)NIH | 1 | Jan 11, 2013 | clinicaltrials |
| NCT00699296 | Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma | terminated | Phase 2 | 4 | Novartis PharmaceuticalsINDUSTRY | 1 | Nov 27, 2012 | clinicaltrials |
| NCT00127881 | Study of Human Monoclonal Antibody to Treat Mycosis Fungoides and Sezary Syndrome | terminated | Phase 3 | 76 | Emergent Product Development Seattle LLCINDUSTRY | 5 | Jul 26, 2012 | clinicaltrials |
| NCT01143311 | Role of microRNA in the Development of Cutaneous Squamous Cell Carcinoma | terminated | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Jun 1, 2011 | clinicaltrials |
| NCT01116154 | Vorinostat and Lenalidomide in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma or Non-Hodgkin Lymphoma | terminated | Phase 1 | 30 | City of Hope Medical CenterOTHER | 1 | Dec 9, 2010 | clinicaltrials |
| NCT00630903 | PUVA Versus PUVA + IFN Alpha 2a in Mycosis Fungoides(MF99) | terminated | Phase 4 | 54 | Madrilenian Group of Cutaneous LymphomasOTHER | 1 | Mar 7, 2008 | clinicaltrials |
| NCT00496743 | Study of Low-Dose Total Skin Electron Beam Therapy in Mycosis Fungoides | terminated | N/A | 10 | Bispebjerg HospitalOTHER | 0 | Jul 4, 2007 | clinicaltrials |
Data updated 22 days agoSource updated Apr 12, 2018source: clinicaltrials